Overall, these results demonstrated that nanocarriers of optimum size and suitable PSMA-targeting ligands may be a potential scaffold to improve PSMA-targeted uptake in EPR-low PCa for imaging and therapy. Here, FOLH1 is linked to posterior cortical atrophy.